Loading clinical trials...
Loading clinical trials...
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Conditions
Interventions
Aflibercept
OPT-302
+1 more
Locations
53
United States
Opthea Investigational Site
Phoenix, Arizona, United States
Opthea Investigational Site
Bakersfield, California, United States
Opthea Investigational Site
Beverly Hills, California, United States
Opthea Investigational Site
Redlands, California, United States
Opthea Investigational Site
Sacramento, California, United States
Opthea Investigational Site
Santa Ana, California, United States
Start Date
January 16, 2018
Primary Completion Date
March 26, 2020
Completion Date
June 11, 2020
Last Updated
April 22, 2025
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT06701721
Lead Sponsor
Opthea Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions